Anouk Kirsten Trip

Anouk Kirsten Trip

Auto-generated profile, based on publicly available information

Anouk Kirsten Trip


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2023 in Research Involvement and Engagement
Verified
Journal Article
Open access
PDF file
MCMille Guldager Christiansen
Mille Guldager Christiansen
HPHelle Pappot
Helle Pappot
CHClayon Hamilton
Clayon Hamilton
TLTrine Lund-Jacobsen
Trine Lund-Jacobsen
AKAnne Wilhøft Kristensen
Anne Wilhøft Kristensen
KPKarin Piil
Karin Piil
Background: Patient and Public Involvement (PPI) in health research is gaining increased attention and acceptance worldwide. Reliable measurements are crucial to accurately assess, monitor, and evaluate patient involvement efforts in research. The Patient Engagement in Research Scale (PEIRS-22) measures meaningful patient and family caregiver engagement in research. This study focuses on three primary objectives: (1) translation of the PEIRS-22 from English to Danish, followed by linguistic validation and cultural adaptation; (2) assessing the applicability of the Danish PEIRS-22; and (3) focus group interviews to explore the user experiences of PPI. Methods: A three-phase multi-method study was conducted. In phase one, the PEIRS-22 was translated, linguistically validated and culturally adapted to Danish. In phase two individuals from three distinct patient cancer advisory boards responded to the Danish version of PEIRS-22 to assess its applicability. Three focus group interviews were conducted in phase three, involving individuals from three patient cancer advisory boards. Results: The translation process resulted in a Danish version of PEIRS-22, conceptually and culturally equivalent to the English version. Overall, among individuals of the three advisory boards (n = 15) the applicability was found to be satisfactory, with no missing data and all items completed. The total PEIRS-22 score among the three advisory boards was 85.2 out of a possible 100, with higher scores indicating greater meaningful involvement. A nested sample of the three patient cancer advisory boards (n = 9) participated in focus group interviews. The analysis yielded four themes: (1) The Danish PEIRS-22 captured the intended cultural meaning and contributed to self-reflection, (2) Internal motivation is a driver for involvement (3), Involvement brought a personal sense of empowerment and (4) Meaningful involvement collaborations are fostered by a trustful atmosphere. Conclusions: The PEIRS-22 questionnaire has been translated, linguistically validated, and culturally adapted into Danish. We propose that the PEIRS-22 is now ready for use in Danish populations. This study provides a Danish version of the questionnaire that can be used to develop patient-centred practices and foster meaningful involvement and collaborations between patients and researchers in the field of cancer research in Denmark. Personal benefits of participating in PPI can vary, and we recommend using PEIRS-22 in conjunction with a qualitative approach to better explore perspectives on meaningful involvement. Trial registration: The study was registered prospectively on October 22, 2022, by the Danish Data Protection Agency (jr. nr. P-2022–528).

6 August 2024 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
KHKim M. Hochreuter
Kim M. Hochreuter
JRJintao Ren
Jintao Ren
JNJasper Nijkamp
Jasper Nijkamp
SKStine S. Korreman
Stine S. Korreman
SLSlávka Lukacova
Slávka Lukacova
ATAnouk K. Trip
Anouk K. Trip
Deep-learning (DL) models for segmentation of the gross tumor volume (GTV) in radiotherapy are generally based on clinical delineations which suffer from inter-observer variability. The aim of this study was to compare performance of a DL-model based on clinical glioblastoma GTVs to a model based on a single-observer edited version of the same GTVs. The dataset included imaging data (Computed Tomography (CT), T1, contrast-T1 (T1C), and fluid-attenuated-inversion-recovery (FLAIR)) of 259 glioblastoma patients treated with post-operative radiotherapy between 2012 and 2019 at a single institute. The clinical GTVs were edited using all imaging data. The dataset was split into 207 cases for training/validation and 52 for testing. GTV segmentation models (nnUNet) were trained on clinical and edited GTVs separately and compared using Surface Dice with 1 mm tolerance (sDSC1mm). We also evaluated model performance with respect to extent of resection (EOR), and different imaging combinations (T1C/T1/FLAIR/CT, T1C/FLAIR/CT, T1C/FLAIR, T1C/CT, T1C/T1, T1C). A Wilcoxon test was used for significance testing. The median (range) sDSC1mm of the clinical-GTV-model and edited-GTV-model both evaluated with the edited contours, was 0.76 (0.43–0.94) vs. 0.92 (0.60–0.98) respectively (p < 0.001). sDSC1mm was not significantly different between patients with a biopsy, partial, and complete resection. T1C as single input performed as good as use of imaging combinations. High segmentation accuracy was obtained by the DL-models. Editing of the clinical GTVs significantly increased DL performance with a relevant effect size. DL performance was robust for EOR and highly accurate using only T1C.

9 August 2023 in Acta Oncologica
Verified
Journal Article
Closed access
VVVishnuga Sivarasah Vamsi
Vishnuga Sivarasah Vamsi
SLSlavka Lukacova
Slavka Lukacova
RDRikke Hedegaard Dahlrot
Rikke Hedegaard Dahlrot
TGTrine Lignell Guldberg
Trine Lignell Guldberg
AKAnders Rosendal Korshøj
Anders Rosendal Korshøj
ATAnouk Kirsten Trip
Anouk Kirsten Trip
The aim of this retrospective registry-based Danish patterns of care study was (1) to evaluate the real-world utilisation of short-course hypofractionated radiotherapy (HFRT) in glioblastoma (GBM) patients over time, and (2) to evaluate the impact of short-course HFRT by assessing trends in multimodality treatment utilisation, compliance, and outcome. Data of all adults with newly diagnosed pathology-confirmed GBM between 2011 and 2019 were extracted from the nationwide Danish Neuro-Oncology Registry. Short-course HFRT was defined as a fraction size of > 2 Gy to a planned dose of > 30 Gy. Patterns of care were assessed. To analyse trends in the assignment to short-course HFRT, and in radiotherapy (RT) compliance, multivariable logistic regression was applied. To analyse trends in survival, multivariable Cox regression was used. In this cohort of 2416 GBM patients, the utilisation of short-course HFRT significantly increased from ca. 10% in 2011 to 33% in recent years. This coincided with the discontinued use of palliative regimens and a decreased use of conventional fractionation. The proportion of patients proceeding to RT remained stable at ca. 85%. The proportion of patients assigned to chemoradiotherapy (CRT) remained stable at ca. 60%; the use of short-course hypofractionated CRT increased with ca. 10%, while the use of conventionally fractionated CRT decreased with ca. 10%. Compliance with conventionally fractionated and short-course HFRT was respective 92% and 93%, and significantly increasing in recent years. In the complete cohort, the median overall survival remained stable at ca. 11 months. Assignment to short-course HFRT was independently associated with shorter survival. In Denmark, the use of short-course HFRT significantly increased in recent years. Nonetheless, the overall utilisation of RT and chemotherapy did not increase on a population level. Nor did survival change. In contrast, compliance with both conventionally fractionated RT and short-course HFRT increased.

6 January 2025 in Neuro-Oncology Advances
Verified
Journal Article
Open access
SCShivani Chiranth
Shivani Chiranth
VFVincent Fougner
Vincent Fougner
ICIb Jarle Christensen
Ib Jarle Christensen
ATAnouk Kirsten Trip
Anouk Kirsten Trip
TCTerkel Christiansen
Terkel Christiansen
TUThomas Urup
Thomas Urup
Background: Infiltrative growth is a hallmark of glioblastoma (GBM) and is a major factor in therapeutic failure. Distant progression is a surrogate marker for infiltrative growth and genetic variants predictive of distant progression may serve as novel treatment targets. The aim was to identify clinical, molecular, radiographic, and genetic factors associated with distant progression in GBM patients. Methods: From our prospective database, all consecutive GBM IDH wild type patients receiving standard therapy (Stupp regimen) from 2016 to 2021 at Rigshospitalet (Denmark) were included. Distant progression was defined as a new contrast-enhancing lesion > 2 cm from the initial lesion. Clinical, molecular, radiographic, and genomic covariates were assessed for association with time to distant progression using Cox analysis. Results: This single-center study included 353 patients, of whom 303 patients had radiographic progression. Distant progression was found in 66 patients (22%) and was associated with poor post-progression survival (P < .001). Unmethylated MGMT (hazard ratio [HR]: 2.54, 95% confidence interval [CI]: 1.62–3.97, P < .001), and multicentric disease at diagnosis (HR: 2.32, 95% CI: 1.28–4.20, P = .005) were associated with a shorter time to distant progression. In patients with a genomic tumor profile (n = 204), the NF1 gene alteration was identified as an independent predictor of distant progression (HR: 3.48, 95% CI: 1.48–8.21, P = .004) and poor survival. Conclusion: Distant progression is an aggressive progression pattern associated with a poor prognosis. Unmethylated MGMT, multicentric disease, and NF1 alteration independently predict distant progression. NF1 alteration may serve as a predictive biomarker for targeted treatment.

9 March 2024 in Neuro-Oncology Practice
Verified
Journal Article
Closed access
PDF file
ATAnouk Kirsten Trip
Anouk Kirsten Trip
RDRikke Hedegaard Dahlrot
Rikke Hedegaard Dahlrot
CHCharlotte Aaquist Haslund
Charlotte Aaquist Haslund
AMAida Muhic
Aida Muhic
AKAnders Rosendal Korshoej
Anders Rosendal Korshoej
SLSlavka Lukacova
Slavka Lukacova
This Danish cohort study aims to (1) compare patterns of care (POC) and survival of patients with multifocal glioblastoma (mGBM) to those with unifocal glioblastoma (uGBM), and (2) explore the association of patient-related factors with treatment assignment and prognosis, respectively, in the subgroup of mGBM patients. Data on all adults with newly diagnosed, pathology-confirmed GBM between 2015-2019 was extracted from the Danish Neuro-Oncology Registry. To compare POC and survival of mGBM to uGBM, we applied multivariable logistic and Cox regression analysis, respectively. To analyze the association of patient-related factors with treatment assignment and prognosis, we established multivariable logistic and Cox regression models, respectively. In this cohort of 1343 patients, 231 had mGBM. Of those, 42% underwent tumor resection and 41% were assigned to long-course chemoradiotherapy. Compared to uGBM, mGBM patients less often underwent a partial (OR 0.4, 95%CI 0.2-0.6), near total (OR 0.1, 95%CI 0.07-0.2), and complete resection (OR 0.1, 95%CI 0.07-0.2) vs biopsy. mGBM patients were furthermore less often assigned to long-course chemoradiotherapy (OR 0.6, 95%CI 0.4-0.97). Median overall survival was 7.0 (95% CI 5.7-8.3) months for mGBM patients, and multifocality was an independent poor prognostic factor for survival (HR 1.3, 95%CI 1.1-1.5). In mGBM patients, initial performance, O[6]-methylguanine-DNA methyltransferase (MGMT) promotor methylation status, and extent of resection were significantly associated with survival. Patients with mGBM were treated with an overall less intensive approach. Multifocality was a poor prognostic factor for survival with a moderate effect. Prognostic factors for patients with mGBM were identified.

18 September 2025 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
LTLaura Toussaint
Laura Toussaint
AHAnne Sophie Lind Helligsø
Anne Sophie Lind Helligsø
LMLudvig Paul Muren
Ludvig Paul Muren
AAAli Amidi
Ali Amidi
RDRikke Hedegaard Dahlrot
Rikke Hedegaard Dahlrot
YLYasmin Lassen-Ramshad
Yasmin Lassen-Ramshad
Background and purpose: Children treated with radiotherapy (RT) for a brain tumour often exhibit neurocognitive impairment and report lower quality of life (QoL) later in life. The aim of this nationwide cross-sectional cohort study was to explore the impact of RT dose to brain organs at risk (OARs) on neurocognition and QoL in long-term survivors of childhood brain tumours. Patient/material and methods: A total of 132 survivors of childhood brain tumours, diagnosed from 2001 to 2017 in Denmark, underwent neurocognitive tests and QoL questionnaires at least 5-years post-diagnosis. Neurocognitive assessments were complete and available for 86 patients (61 no-RT/25 RT), and QoL scores for 107 (79 no-RT/28 RT). Mann Whitney U-tests were used to compare scores between no-RT and RT groups. For scores impacted by RT, OAR-specific robust linear regressions were performed to evaluate RT dose effects while adjusting for potential confounders. Results: Clinically significant overall cognitive impairment was observed for 55% of the neurocognitive sub-cohort, with younger age at treatment time as a significant risk factor, while hydrocephalus status had no impact. There were no statistically significant differences on neurocognitive tests between the RT and no-RT group. However, patients treated with RT had significantly lower scores on the physical and social functioning QoL domains, with mean dose to the pituitary gland and left hippocampus, respectively, as significant predictors. Interpretation: This cross-sectional study indicates that RT dose-effects, particularly in the pituitary gland and left hippocampus, might contribute to reduced QoL in survivors of childhood brain tumours.